Guidelines on endocrine therapy of breast cancer EUSOMA. (Q43935110)

28 November 2017

title

Guidelines on endocrine therapy of breast cancer EUSOMA. (English)

1 reference

28 November 2017

R W Blamey

1

1 reference

28 November 2017

EUSOMA

series ordinal

2

1 reference

28 November 2017

publication date

1 March 2002

1 reference

European Journal of Cancer

28 November 2017

published in

1 reference

28 November 2017

volume

38

1 reference

28 November 2017

issue

5

1 reference

28 November 2017

page(s)

615-634

1 reference

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Estrogen receptor variants in clinical breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Standardization of steroid receptor assays in human breast cancer--II. Samples with low receptor content

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Oestrogen receptor: a stable phenotype in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Prospective evaluation of vitamin E for hot flashes in breast cancer survivors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 r

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Randomized trial of adjuvant tamoxifen and/or goserelin in premenopausal breast cancer--self-rated physiological effects and symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Pregnancy after breast cancer. The relationship of pregnancy to breast cancer development and progression

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

A prognostic index in primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Confirmation of a prognostic index in primary breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Recent advances in the clinical application of aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Tamoxifen hits the target in situ

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Occurrence of stroke with tamoxifen in NSABP B-24

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Locally advanced breast cancer: long-term results of a randomized trial comparing primary treatment with tamoxifen or radiotherapy in post-menopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Locally advanced breast cancer: early results of a randomised trial of multimodal therapy versus initial hormone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Long-term follow-up of elderly patients randomized to primary tamoxifen or wedge mastectomy as initial therapy for operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Letrozole as primary medical therapy for locally advanced and large operable breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

A 40-year-old woman with a strong family history of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for 'well-tolerated' treatments?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900011-4

7 January 2021

10.1016/S0959-8049(02)00011-4

Identifiers

DOI

1 reference

28 November 2017

1 reference